Corrigendum to “Exosomes as drug delivery vehicles for Parkinson's disease therapy” [Journal of Controlled Release 207, (2015) 18–30](S0168365915002138)(10.1016/j.jconrel.2015.03.033);Exosomes as drug delivery vehicles for Parkinson's disease therapy

Journal of Controlled Release

Volumn 207, Issue , 2015, Pages 18-30

  Haney, Matthew J ^a   Klyachko, Natalia L ^a,b   Zhao, Yuling ^a   Gupta, Richa ^a   Plotnikova, Evgeniya G ^b   He, Zhijian ^a   Patel, Tejash ^a   Piroyan, Aleksandr ^a   Sokolsky, Marina ^a   Kabanov, Alexander V ^a,b   Batrakova, Elena V ^a  

^a University of North Carolina at Chapel Hill   (United States)

^b MOSCOW STATE UNIVERSITY   (Russian Federation)

Author keywords

Blood brain barrier; Catalase; Exosomes; Neuroinflammation; Oxidative stress; Parkinson's disease

Indexed keywords

ADHESIVES; CONTROLLED DRUG DELIVERY; DISEASE CONTROL; DRUG PRODUCTS; EXTRUSION; LIPID BILAYERS; MACROPHAGES; OXIDATIVE STRESS; TARGETED DRUG DELIVERY;

BLOOD-BRAIN BARRIER; CATALASE; EXOSOMES; NEUROINFLAMMATION; PARKINSON'S DISEASE;

NEURODEGENERATIVE DISEASES;

ANTIPARKINSON AGENT; CATALASE; GOLD NANOPARTICLE; LIPOSOME; POLYGLACTIN; PROTEINASE; SAPONIN; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; DRUG CARRIER; NANOPARTICLE; NEUROPROTECTIVE AGENT; OXIDOPAMINE;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BRAIN; CIRCULATION TIME; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG TARGETING; ENZYME ACTIVITY; EX VIVO STUDY; EXOSOME; FEMALE; IMMUNOGENICITY; IN VITRO STUDY; MACROPHAGE; MICROGLIA; MOLECULAR WEIGHT; MONOCYTE; MONONUCLEAR PHAGOCYTE; MOUSE; NERVE CELL; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PC12 CELL LINE; PRIORITY JOURNAL; PROTEIN DEGRADATION; SUSTAINED DRUG RELEASE; TARGET CELL; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; INTRANASAL DRUG ADMINISTRATION; KINETICS; MEDICINAL CHEMISTRY; METABOLISM; NANOMEDICINE; PARKINSONIAN DISORDERS; PHARMACEUTICS; PROCEDURES; RAT; RAW 264.7 CELL LINE; SOLUBILITY;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; ANTIPARKINSON AGENTS; BRAIN; CATALASE; CHEMISTRY, PHARMACEUTICAL; DISEASE MODELS, ANIMAL; DRUG CARRIERS; EXOSOMES; FEMALE; KINETICS; MICE; MICE, INBRED C57BL; NANOMEDICINE; NANOPARTICLES; NEURONS; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; OXIDOPAMINE; PARKINSONIAN DISORDERS; PC12 CELLS; RATS; RAW 264.7 CELLS; SOLUBILITY; TECHNOLOGY, PHARMACEUTICAL;

EID: 84926451271     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2021.09.027     Document Type: Erratum

References (93)

1. P.L. Mcgeer, S. Itagaki, B.E. Boyes, and E.G. Mcgeer Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains Neurology 38 8 1988 1285 1291
2. J. Busciglio, and B.A. Yankner Apoptosis and increased generation of reactive oxygen species in Down's syndrome neurons in vitro Nature 378 6559 1995 776 779
3. M. Ebadi, S.K. Srinivasan, and M.D. Baxi Oxidative stress and antioxidant therapy in Parkinson's disease Prog. Neurobiol. 48 1 1996 1 19
4. D.C. Wu, P. Teismann, and K. Tieu NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease Proc. Natl. Acad. Sci. U. S. A. 100 10 2003 6145 6150
5. L.M. Ambani, M.H. Van Woert, and S. Murphy Brain peroxidase and catalase in Parkinson disease Arch. Neurol. 32 2 1975 114 118
6. P. Riederer, E. Sofic, and W.D. Rausch Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains J. Neurochem. 52 2 1989 515 520
7. S. Abraham, C.C. Soundararajan, S. Vivekanandhan, and M. Behari Erythrocyte antioxidant enzymes in Parkinson's disease Indian J. Med. Res. 121 2 2005 111 115
8. W.M. Pardridge Drug transport across the blood-brain barrier J. Cereb. Blood Flow Metab. 32 11 2012 1959 1972
9. A.V. Kabanov, and E.V. Batrakova Polymer nanomaterials H.E. Gendelman, T. Ikezu, Neuroimmune Pharmacology 2008 Springer Omaha 691 707
10. G.A. Silva Nanotechnology applications and approaches for neuroregeneration and drug delivery to the central nervous system Ann. N. Y. Acad. Sci. 1199 2010 221 230
11. Q. Peng, S. Zhang, and Q. Yang Preformed albumin corona, a protective coating for nanoparticles based drug delivery system Biomaterials 34 33 2013 8521 8530
12. J.S. Beckman, R.L. Minor Jr., C.W. White, J.E. Repine, G.M. Rosen, and B.A. Freeman Superoxide dismutase and catalase conjugated to polyethylene glycol increases endothelial enzyme activity and oxidant resistance J. Biol. Chem. 263 14 1988 6884 6892
13. K. Yoshida, G.F. Burton, J.S. Mckinney, H. Young, and E.F. Ellis Brain and tissue distribution of polyethylene glycol-conjugated superoxide dismutase in rats Stroke 23 6 1992 865 869
14. F.M. Veronese, P. Caliceti, O. Schiavon, and M. Sergi Polyethylene glycol-superoxide dismutase, a conjugate in search of exploitation Adv. Drug Deliv. Rev. 54 4 2002 587 606
15. E.T. Dams, P. Laverman, and W.J. Oyen Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes J. Pharmacol. Exp. Ther. 292 3 2000 1071 1079
16. T. Ishida, R. Maeda, M. Ichihara, K. Irimura, and H. Kiwada Accelerated clearance of PEGylated liposomes in rats after repeated injections J. Control. Release 88 1 2003 35 42
17. T. Ishida, S. Kashima, and H. Kiwada The contribution of phagocytic activity of liver macrophages to the accelerated blood clearance (ABC) phenomenon of PEGylated liposomes in rats J. Control. Release 126 2 2008 162 165
18. J.K. Armstrong, G. Hempel, and S. Koling Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients Cancer 110 1 2007 103 111
19. G. Garratty Modulating the red cell membrane to produce universal/stealth donor red cells suitable for transfusion Vox Sang. 94 2 2008 87 95
20. R.C. Lai, R.W. Yeo, K.H. Tan, and S.K. Lim Exosomes for drug delivery - a novel application for the mesenchymal stem cell Biotechnol. Adv. 31 5 2012 543 551
21. K.B. Johnsen, J.M. Gudbergsson, M.N. Skov, L. Pilgaard, T. Moos, and M. Duroux A comprehensive overview of exosomes as drug delivery vehicles - endogenous nanocarriers for targeted cancer therapy Biochim. Biophys. Acta 1846 1 2014 75 87
22. Y. Tian, S. Li, and J. Song A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy Biomaterials 35 7 2014 2383 2390
23. A.V. Vlassov, S. Magdaleno, R. Setterquist, and R. Conrad Exosomes: current knowledge of their composition, biological functions, and diagnostic and therapeutic potentials Biochim. Biophys. Acta 1820 7 2012 940 948
24. C. Thery, S. Amigorena, G. Raposo, and A. Clayton Isolation and characterization of exosomes from cell culture supernatants and biological fluids Curr. Protoc. Cell Biol. 2006 2 5 (Chapter 3, Unit 3.22)
25. S. Bhatnagar, K. Shinagawa, F.J. Castellino, and J.S. Schorey Exosomes released from macrophages infected with intracellular pathogens stimulate a proinflammatory response in vitro and in vivo Blood 110 9 2007 3234 3244
26. A. Clayton, A. Turkes, H. Navabi, M.D. Mason, and Z. Tabi Induction of heat shock proteins in B-cell exosomes J. Cell Sci. 118 Pt 16 2005 3631 3638
27. E.N. Nolte-'T Hoen, S.I. Buschow, S.M. Anderton, W. Stoorvogel, and M.H. Wauben Activated T cells recruit exosomes secreted by dendritic cells via LFA-1 Blood 113 9 2009 1977 1981
28. R.M. Johnstone The Jeanne Manery-Fisher Memorial Lecture 1991. Maturation of reticulocytes: formation of exosomes as a mechanism for shedding membrane proteins Biochem. Cell Biol. 70 3-4 1992 179 190
29. A. Zomer, T. Vendrig, E.S. Hopmans, M. Van Eijndhoven, J.M. Middeldorp, and D.M. Pegtel Exosomes: fit to deliver small RNA Commun. Integr. Biol. 3 5 2010 447 450
30. H. Valadi, K. Ekstrom, A. Bossios, M. Sjostrand, J.J. Lee, and J.O. Lotvall Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells Nat. Cell Biol. 9 6 2007 654 659
31. C. Thery, M. Ostrowski, and E. Segura Membrane vesicles as conveyors of immune responses Nat. Rev. Immunol. 9 8 2009 581 593
32. J. Skog, T. Wurdinger, and S. Van Rijn Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers Nat. Cell Biol. 10 12 2008 1470 1476
33. L. Alvarez-Erviti, Y. Seow, H. Yin, C. Betts, S. Lakhal, and M.J. Wood Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes Nat. Biotechnol. 29 4 2011 341 345
34. S. Lakhal, and M.J. Wood Exosome nanotechnology: an emerging paradigm shift in drug delivery: exploitation of exosome nanovesicles for systemic in vivo delivery of RNAi heralds new horizons for drug delivery across biological barriers Bioessays 33 10 2011 737 741
35. J.G. Van Den Boorn, M. Schlee, C. Coch, and G. Hartmann SiRNA delivery with exosome nanoparticles Nat. Biotechnol. 29 4 2011 325 326
36. X. Zhuang, X. Xiang, and W. Grizzle Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain Mol. Ther. 19 10 2011 1769 1779
37. C.P. Lai, and X.O. Breakefield Role of exosomes/microvesicles in the nervous system and use in emerging therapies Front. Physiol. 3 2012 228
38. S. El Andaloussi, S. Lakhal, I. Mager, and M.J. Wood Exosomes for targeted siRNA delivery across biological barriers Adv. Drug Deliv. Rev. 65 3 2013 391 397
39. Y. Lee, S. El Andaloussi, and M.J. Wood Exosomes and microvesicles: extracellular vesicles for genetic information transfer and gene therapy Hum. Mol. Genet. 21 R1 2012 R125 R134
40. C.M. Hu, L. Zhang, S. Aryal, C. Cheung, and R.H. Fang Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform Proc. Natl. Acad. Sci. U. S. A. 108 27 2011 10980 10985
41. S.C. Jang, O.Y. Kim, and C.M. Yoon Bioinspired exosome-mimetic nanovesicles for targeted delivery of chemotherapeutics to malignant tumors ACS Nano 8 4 2013 e61852
42. R.C. Lai, F. Arslan, and M.M. Lee Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury Stem Cell Res. 4 3 2010 214 222
43. M.J. Haney, P. Suresh, and Y. Zhao Blood-borne macrophage-neural cell interactions hitchhike endosome networks for cell-based nanozyme brain delivery Nanomedicine (London) 7 6 2012 815 833
44. M.J. Haney, Y. Zhao, and E.B. Harrison Specific transfection of inflamed brain by macrophages: a new therapeutic strategy for neurodegenerative diseases PLoS One 8 4 2013 e61852
45. M.J. Haney, Y. Zhao, and S. Li Cell-mediated transfer of catalase nanoparticles from macrophages to brain endothelial, glial and neuronal cells Nanomedicine (London) 6 7 2011 1215 1230
46. A.M. Brynskikh, Y. Zhao, and R.L. Mosley Macrophage delivery of therapeutic nanozymes in a murine model of Parkinson's disease Nanomedicine (London) 5 3 2010 379 396
47. R.D. Brinton A women's health issue: Alzheimer's disease and strategies for maintaining cognitive health Int. J. Fertil. Women's Med. 44 4 1999 174 185
48. I. Gozes Neuroprotective peptide drug delivery and development: potential new therapeutics Trends Neurosci. 24 12 2001 700 705
49. R.A. Kroll, and E.A. Neuwelt Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means Neurosurgery 42 5 1998 1083 1099 (discussion 1099-1100)
50. A. Bachis, and I. Mocchetti Brain-derived neurotrophic factor is neuroprotective against human immunodeficiency virus-1 envelope proteins Ann. N. Y. Acad. Sci. 1053 2005 247 257
51. J. Ying Wang, F. Peruzzi, and A. Lassak Neuroprotective effects of IGF-I against TNFalpha-induced neuronal damage in HIV-associated dementia Virology 305 1 2003 66 76
52. V.E. Koliatsos, R.E. Clatterbuck, and H.J. Nauta Human nerve growth factor prevents degeneration of basal forebrain cholinergic neurons in primates Ann. Neurol. 30 6 1991 831 840
53. D. Dogrukol-Ak, W.A. Banks, N. Tuncel, and M. Tuncel Passage of vasoactive intestinal peptide across the blood-brain barrier Peptides 24 3 2003 437 444
54. R.J. Desnick, and E.H. Schuchman Enzyme replacement and enhancement therapies: lessons from lysosomal disorders Nat. Rev. Genet. 3 12 2002 954 966
55. A. Urayama, J.H. Grubb, W.S. Sly, and W.A. Banks Developmentally regulated mannose 6-phosphate receptor-mediated transport of a lysosomal enzyme across the blood-brain barrier Proc. Natl. Acad. Sci. U. S. A. 101 34 2004 12658 12663
56. H. Dou, C.J. Destache, and J.R. Morehead Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery Blood 108 8 2006 2827 2835
57. J. Pruszak, L. Just, O. Isacson, and G. Nikkhah Isolation and culture of ventral mesencephalic precursor cells and dopaminergic neurons from rodent brains Curr. Protoc. Stem Cell Biol. 2009 3 7 (Chapter 2, Unit 2D 5)
58. T. Bronich, H. Nguyen, A. Eisenberg, and A. Kabanov Recognition of DNA topology in reactions between plasmid DNA and cationic copolymers J. Am. Chem. Soc. 122 35 2000 8339 8343
59. S. Vinogradov, E. Batrakova, and A. Kabanov Poly(ethylene glycol)-polyethyleneimine NanoGel (TM) particles: novel drug delivery systems for antisense oligonucleotides Colloids Surf. B Biointerfaces 16 1-4 1999 291 304
60. Y. Zhao, M.J. Haney, and N.L. Klyachko Polyelectrolyte complex optimization for macrophage delivery of redox enzyme nanoparticles Nanomedicine (London) 6 1 2011 25 42
61. S. Giovagnoli, P. Blasi, M. Ricci, and C. Rossi Biodegradable microspheres as carriers for native superoxide dismutase and catalase delivery AAPS PharmSciTech 5 4 2004 e51
62. E.V. Batrakova, S. Li, and A.D. Reynolds A macrophage-nanozyme delivery system for Parkinson's disease Bioconjug. Chem. 18 5 2007 1498 1506
63. J.W. Tan, C.L. Tham, D.A. Israf, S.H. Lee, and M.K. Kim Neuroprotective effects of biochanin a against glutamate-induced cytotoxicity in PC12 cells via apoptosis inhibition Neurochem. Res. 38 3 2013 512 518
64. E.V. Batrakova, S.V. Vinogradov, S.M. Robinson, M.L. Niehoff, W.A. Banks, and A.V. Kabanov Polypeptide point modifications with fatty acid and amphiphilic block copolymers for enhanced brain delivery Bioconjug. Chem. 16 4 2005 793 802
65. Y. Zhao, M.J. Haney, and V. Mahajan Active targeted macrophage-mediated delivery of catalase to affected brain regions in models of Parkinson's disease J. Nanomed. Nanotechnol. S4 2011
66. K. Tieu, C. Perier, and C. Caspersen D-beta-hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease J. Clin. Invest. 112 6 2003 892 901
67. G.I. Keshet, R.J. Tolwani, and A. Trejo Increased host neuronal survival and motor function in BMT Parkinsonian mice: involvement of immunosuppression J. Comp. Neurol. 504 6 2007 690 701
68. M. Papathanou, S. Rose, A. Mccreary, and P. Jenner Induction and expression of abnormal involuntary movements is related to the duration of dopaminergic stimulation in 6-OHDA-lesioned rats Eur. J. Neurosci. 33 12 2011 2247 2254
69. S. Papadopoulos, K.D. Jurgens, and G. Gros Protein diffusion in living skeletal muscle fibers: dependence on protein size, fiber type, and contraction Biophys. J. 79 4 2000 2084 2094
70. Y.Z. Zhou, R.G. Alany, V. Chuang, and J. Wen Optimization of PLGA nanoparticles formulation containing l-DOPA by applying the central composite design Drug Dev. Ind. Pharm. 39 2 2013 321 330
71. V.G. Kucherianu, V.V. Iurasov, and G.N. Kryzhanovskii The effect of liposomal form of l-Dopa on the development of parkinsonian syndrome in mice Biull. Eksp. Biol. Med. 123 1 1997 29 33
72. D.K. Stone, A.D. Reynolds, R.L. Mosley, and H.E. Gendelman Innate and adaptive immunity for the pathobiology of Parkinson's disease Antioxid. Redox Signal. 11 9 2009 2151 2166
73. C. Fruhbeis, D. Frohlich, and E.M. Kramer-Albers Emerging roles of exosomes in neuron-glia communication Front. Physiol. 3 2012 119
74. J. Lotvall, and H. Valadi Cell to cell signalling via exosomes through esRNA Cell Adhes. Migr. 1 3 2007 156 158
75. H. Jin, A. Kanthasamy, A. Ghosh, V. Anantharam, B. Kalyanaraman, and A.G. Kanthasamy Mitochondria-targeted antioxidants for treatment of Parkinson's disease: preclinical and clinical outcomes Biochim. Biophys. Acta 1842 8 2014 1282 1294
76. K.M. Lucin, and T. Wyss-Coray Immune activation in brain aging and neurodegeneration: too much or too little? Neuron 64 1 2009 110 122
77. P.H. Chan Reactive oxygen radicals in signaling and damage in the ischemic brain J. Cereb. Blood Flow Metab. 21 1 2001 2 14
78. D.C. Wu, V. Jackson-Lewis, and M. Vila Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease J. Neurosci. 22 5 2002 1763 1771
79. Y. Du, Z. Ma, and S. Lin Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease Proc. Natl. Acad. Sci. U. S. A. 98 25 2001 14669 14674
80. I. Kurkowska-Jastrzebska, M. Babiuch, I. Joniec, A. Przybylkowski, A. Czlonkowski, and A. Czlonkowska Indomethacin protects against neurodegeneration caused by MPTP intoxication in mice Int. Immunopharmacol. 2 8 2002 1213 1218
81. P. Teismann, and B. Ferger Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease Synapse 39 2 2001 167 174
82. B. Ferger, P. Teismann, C.D. Earl, K. Kuschinsky, and W.H. Oertel Salicylate protects against MPTP-induced impairments in dopaminergic neurotransmission at the striatal and nigral level in mice Naunyn Schmiedeberg's Arch. Pharmacol. 360 3 1999 256 261
83. B. Ferger, C. Spratt, C.D. Earl, P. Teismann, W.H. Oertel, and K. Kuschinsky Effects of nicotine on hydroxyl free radical formation in vitro and on MPTP-induced neurotoxicity in vivo Naunyn Schmiedeberg's Arch. Pharmacol. 358 3 1998 351 359
84. J. Peng, F.F. Stevenson, S.R. Doctrow, and J.K. Andersen Superoxide dismutase/catalase mimetics are neuroprotective against selective paraquat-mediated dopaminergic neuron death in the substantial nigra: implications for Parkinson disease J. Biol. Chem. 280 32 2005 29194 29198
85. K.N. Prasad, W.C. Cole, and A.R. Hovland Multiple antioxidants in the prevention and treatment of neurodegenerative disease: analysis of biologic rationale Curr. Opin. Neurol. 12 6 1999 761 770
86. R.A. Gonzalez-Polo, G. Soler, A. Rodriguezmartin, J.M. Moran, and J.M. Fuentes Protection against MPP + neurotoxicity in cerebellar granule cells by antioxidants Cell Biol. Int. 28 5 2004 373 380
87. E.J. Pappert, C.C. Tangney, and C.G. Goetz Alpha-tocopherol in the ventricular cerebrospinal fluid of Parkinson's disease patients: dose-response study and correlations with plasma levels Neurology 47 4 1996 1037 1042
88. M.C. Jamur, and C. Oliver Permeabilization of cell membranes Methods Mol. Biol. 588 2010 63 66
89. S. Rana, S. Yue, D. Stadel, and M. Zoller Toward tailored exosomes: the exosomal tetraspanin web contributes to target cell selection Int. J. Biochem. Cell Biol. 44 9 2012 1574 1584
90. F. Danhier, E. Ansorena, J.M. Silva, R. Coco, A. Le Breton, and V. Preat PLGA-based nanoparticles: an overview of biomedical applications J. Control. Release 161 2 2012 505 522
91. C. Spuch, and C. Navarro Liposomes for targeted delivery of active agents against neurodegenerative diseases (Alzheimer's disease and Parkinson's disease) J. Drug Deliv. 2011 2011 469679
92. H. Braak, K. Del Tredici, U. Rub, R.A. De Vos, E.N. Jansen Steur, and E. Braak Staging of brain pathology related to sporadic Parkinson's disease Neurobiol. Aging 24 2 2003 197 211
93. F.J. Muller, E.Y. Snyder, and J.F. Loring Gene therapy: can neural stem cells deliver? Nat. Rev. Neurosci. 7 1 2006 75 84